This study tests if a combination of two drugs, durvalumab and bevacizumab, is safe and effective for treating liver cancer called Hepatocellular Carcinoma (HCC) that can't be removed by surgery. The treatment uses a method called Transarterial Radioembolization (TARE), where tiny radioactive beads (Yttrium 90) are used to target the cancer. Participants must have HCC that is suitable for this treatment and cannot have it cured by surgery or liver transplant.

The study takes place in the US and plans to include about 125 participants at 20 locations. To join, participants need to meet certain health conditions, like having a good liver function and no cancer outside the liver. They must also not have serious heart disease, uncontrolled high blood pressure, or a history of certain health issues. Participants who have had more than one similar treatment or certain prior cancer treatments are excluded.

• The study is conducted at about 20 sites in the US.
• Participants need to meet specific health criteria.
• Prior similar treatments might exclude participation.